A new executive order calls for FDA to promote domestic manufacturing, but with plenty of practical concerns

By Rachel Coe, MSc

On May 5, 2025, President Trump issued an executive order to promote domestic production of critical medicines via “regulatory relief.” The order is meant to address U.S. reliance on biopharmaceutical manufacturing operations located in part or in whole on foreign soil. The new order would promote domestic manufacturing by cutting down on regulatory barriers, potentially including “unannounced inspections of domestic manufacturers” by the FDA.

Fill out the form to read the full analysis.

Required *

Introducing Inspection Navigator

Stay ahead of enforcement shifts with complete visibility, right when you need it most. Inspection Navigator gives regulatory teams a faster, smarter way to view FDA inspection trends, access critical 483s, and align compliance strategies—all in one intuitive platform.

This new tool allows you to:

Spot trends across product types and regions
Anticipate where the FDA is focusing next
Benchmark your site or company’s inspection history
Make strategic decisions with confidence